Schering PTO patent extension proposal
Executive Summary
Schering's proposal that would extend the patent for the allergy drug Claritin and other "pipeline" products has not been included in omnibus appropriations bill. The measure is said to have been originally supported by Sen. Mack (R-Fla.) but later championed by Sen. Lautenberg (D-N.J.). The Clinton Administration is said to oppose a three-year patent extension proposal being pushed by Schering-Plough following an Oct. 9 letter from Sens. Durbin (D-Ill.) and Leahy (D-Vt.) to White House Chief of Staff Erskine Bowles. Senate Majority Leader Lott (R-Miss.) is also understood to oppose the measure, under which the U.S. Patent & Trademark Office would review applications for an extension of up to three years for "pipeline" drugs that were already submitted to FDA when Waxman-Hatch passed, but for which approval was delayed. Products under an IND when Waxman-Hatch was signed into law were limited to two-year patent extensions. The proposal would affect seven drugs
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth